Amitifadine

Amitifadine
Clinical data
Pronunciation	(/æmɪˈtɪfədiːn/ am-i-TIF-ə-deen)
Other names	DOV-21,947; EB-1010
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name (1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane;
CAS Number	410074-73-6;
PubChem CID	11658655;
ChemSpider	9833390 ;
UNII	GE0J375F8F;
KEGG	D10088 ;
ChEMBL	ChEMBL592374 ;
CompTox Dashboard (EPA)	DTXSID001025835 ;
Chemical and physical data
Formula	C11H11Cl2N
Molar mass	228.12 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1[C@@](CN2)(C1C2)C(=C1)C=C(C(Cl)=C1)Cl;
	InChI InChI=1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2/t8-,11+/m1/s1 ; Key:BSMNRYCSBFHEMQ-KCJUWKMLSA-N ;
	(verify)

Amitifadine (developmental code names DOV-21,947, EB-1010) is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) or so-called triple reuptake inhibitor (TRI) which is or was being developed by Euthymics Bioscience. It was under development for the treatment of major depressive disorder, but in May 2013, it was reported that the drug failed to show superior efficacy to placebo in a phase IIb/IIIa clinical trial. it was suggested that this may have been due to the drug being underdosed. In September 2017, development of amitifadine for the treatment of major depressive disorder was finally officially discontinued. As of September 2017, it is still listed as being under development for the treatment of alcoholism and smoking withdrawal.